AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05575882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Potential of hydrogen measurement (pH)
Description: pH measurement outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
Study NCT05575882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Potential of hydrogen measurement (pH)
Description: pH measurement outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
Study NCT05575882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical evaluation of atopic dermatitis
Description: EASI score on each visit. Non invasive technique.
Study NCT05575882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Clinical evaluation of atopic dermatitis
Description: EASI score on each visit. Non invasive technique.
Study NCT05575882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life assessment
Description: Cardiff questionnaires to assess quality of life of subjects and their family members.
Study NCT05575882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality of life assessment
Description: Cardiff questionnaires to assess quality of life of subjects and their family members.
Study NCT05575882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of the effect on itching and sleep disturbances
Description: Visual analogue scale from 0 to 10
Study NCT05575882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of the effect on itching and sleep disturbances
Description: Visual analogue scale from 0 to 10
Study NCT05575882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of the tolerance of the study product or placebo
Description: By collection of Adverse Events (AEs) on daily log and electronic Case Report Form (eCRF).
Study NCT05575882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of the tolerance of the study product or placebo
Description: By collection of Adverse Events (AEs) on daily log and electronic Case Report Form (eCRF).
Study NCT03875053 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Patients wear the home sleep apnea machine overnight. Patients undergoing standard of care CRT wear the home sleep apnea machine a second time 3 months after completion of CRT.
Study NCT03875053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03875053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06329076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Administration of losartan tablets (50 mg)
Study NCT06329076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo tablets
Study NCT04902027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
Description: All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
Study NCT06573151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor, anti-PD-1 antibody and P-GemOx
Description: Selinexor, 40mg, qw, po; Pegaspargase, 2500U/m2, IM, d1; Gemcitabine, 1000mg/m2, i.v., d1, d8; Oxaliplatin, 130mg/m2, i.v., d1; anti-PD1 antibody, 200mg, d2, i.v. (21d cycle);
Study NCT05924828 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT06543134 — intervention group
Intervention type: PROCEDURE
Intervention: surgery
Description: ENT surgery lasting more than half an hour
Study NCT06543134 — intervention group
Intervention type: PROCEDURE
Intervention: sedation scale
Description: Measurement of postoperative recovery with the Richmond agitation scale and the Riker sedation scale
Study NCT05016765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active, self-directed electrical stimulation of the median nerve
Description: Electrical stimulation of the median nerve (12 Hz, pulse width 200µs), initially at the threshold needed to see movement of the right thumb with stimulation. After initial training with the device and education in the rationale for suprathreshold stimulation, participants will choose timing and intensity of stimulation based on their momentary symptom severity and their experience with the treatment since the beginning of the study. Participant can choose right or left median nerve (we will suggest their nondominant hand to minimize interference with daily activities).
Study NCT06459076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE)
Description: Immediately after ceasing assisted ventilation, before intubation the age-appropriate nasal prongs were applied and weight-specific high flow rates delivered using the Optiflow THRIVETM system. The flow rates applied were as follows: 0-15 kg, 2 litres kg-1 min-1；15-30 kg, 35 litres min-1; 30-50 kg, 40 litres min-1; and>50 kg, 50 litres min-1.
Study NCT04861831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power Centering for Seniors intervention
Description: Power Centering for Seniors is an innovative East-meets-West intervention (75-minute, twice weekly, supervised group classes over 12 weeks) that integrates Western best practice muscle strength and balance training components with Chinese Tai Chi/Qi Gong to improve mobility and quality of life in older, community-dwelling adults. Home practice is recommended (approximately 30 minutes three times per week on non-course days). The modularly designed course consists of four cycles with six themes repeated in each cycle. Course exercises increase in intensity throughout the twelve-week intervention period. Repetition of cycles and themes prepares participants for continuing their individualized version of the program after the group course intervention is complete. This should lead to long-term practice of the exercises learned in the intervention and to sustained positive effects of the training.
Study NCT06123494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811 6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle
Study NCT06123494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
Description: Ramucirumab 8mg/kg，D 1,15 + Paclitaxel 80mg/m2，D1,8,15，Q4W; Paclitaxel 80mg/m2，D1,8,15，Q4W; Docetaxel 75mg/m2，D1，Q3W; Irinotecan 150mg/m2，D1，Q2W.
Study NCT05486663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tactile/kinesthetic Group
Description: Tactile/kinesthetic stimulation is performed in three stages. In the first stage; for tactile stimulation; The baby is placed in the prone (prone) position in the incubator. Light massage was applied in the head, shoulder, back, legs and arms of the infants. Each massage is applied 12 times for 1 minute. Massage was performed for 5 seconds. In the second stage Kinesthetic stimulation, including elbow flexion-extension movement, palm massages, flexion-extension of the knees and legs and plantar massages, was applied while the neonate was in supine position. Each kinesthetic stimulation was performed for 5 seconds. Each movement was repeated six times, with a total duration of 5 minutes. Tactile stimulation was repeated once after kinesthetic stimulation. The total duration of TKS was 15 minutes which was performed three times daily preferably between breastfeeding or bottle feeding for 14 consecutive days.
Study NCT06038149 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiogram
Description: A painless ultrasound scan of the heart.
Study NCT06203288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based social and emotional learning (MBSEL) program for educators
Description: MBSEL for educators is a program designed to improve teachers' ability to deal with stress and enhance their well-being and teaching. Lessons include: (1) Introduction to the Science, (2) Brain, Attention, \& Well-being, (3) Positive Neuroscience, (4) Mindful Teaching, (5) Embracing Self-Compassion, (6) Finding Your Compass: Intentions for Mindful Living. This 2-hour program is self-paced and delivered online.
Study NCT06203288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based social and emotional learning (MBSEL) program for students
Description: MBSEL program for students consists of 17 lessons taught about once a week (40-50 minutes per lesson). The core mindfulness program practices (done every day for 3 minutes three times a day) consist of focusing on one's breathing and attentive listening to a single resonant sound. The lessons focus on promoting prosocial behavior (e.g., kindness, altruism), resiliency, well-being, and reducing stress in students. It also incorporates an eco-behavioral systems orientation.
Study NCT04688437 — intervention group
Intervention type: RADIATION
Intervention: standard standing-sitting posteroanterior and lateral whole spine X-ray and lumbar MRI examination
Description: Routine examination
Study NCT05158062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab 200 mg every three weeks (Q3W)
Study NCT05158062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: olaparib 300 mg twice daily (BID) during maintenance period
Study NCT05158062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab 15 mg/kg Q3W
Study NCT05158062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin AUC=5 or 6 Q3W during treatment period
Study NCT05158062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 175 mg/m2 Q3W during treatment period
Study NCT05158062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel 60 \~ 70 mg/m2 Q3W during treatment period
Study NCT05587517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMPOWER
Description: EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment.
Study NCT05587517 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Conversation
Description: The Supportive Conversation will match the time and attention offered through EMPOWER, so will be about 1.5-2 hours and will have two additional follow-up calls.
Study NCT05800743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® Ascending Stent Graft (ASG device)
Description: Endovascular aortic repair of the ascending aorta
Study NCT05800743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® Thoracic Aortic Graft Thoracic Branch Endoprosthesis (TBE Device)
Description: Endovascular aortic repair of the ascending aorta/aortic arch
Study NCT05800743 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Open surgical repair of the ascending aorta and/or the aortic arch
Study NCT05218317 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: in-vivo Corneal Confocal Microscopy
Description: All study subjects underwent IVCM (Rostock Cornea Module, Heidelberg Retinal Tomograph III; Heidelberg Engineering, Germany). Before the examination, two drops of topical anesthetic with proparacaine hydrochloride (Alcaine 0.5%, Alcon-Couvreur, Belgium) were applied to both eyes. A carbomer-based gel (Viscotears 0.2%; Dr. Gerhard Mann, Chem.- Pharm. Fabrik, Germany) was used as the coupling agent between the cornea and the applanating cap of IVCM. For correctly positioning the central cornea, all subjects were asked to fixate a determined fixation point and controlled with the device camera. All scans were performed in approximately 5 minutes for each eye by a single experienced ophthalmologist, masked from the subject's disease status.
Study NCT06538454 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: The exercises will be the same in both stages: squat, bench press, stiff, rowing, hip thrust and shoulder press. Futhermore, the rest interval (2 minutes) and the exercise order (alterning upper and lower limbs) also will be the same in the stages.~In the chronic experiment, the resistance training will be carried for 10 weeks with 2 weekly sessions in alternate days. The sets in both groups will be carried close to muscle failure.~The difference between groups is the intensity, who reflects the repetition zone. The 80%1RM group will be perform 8-10 repetitions per set, while the 60%1RM group will be perform 18-20 repetitions.
Study NCT05653518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem t:slim X2 with Control-IQ Technology
Description: FDA approved Tandem t:slim insulin pump with Control-IQ Technology and the Dexcom G6 CGM
Study NCT05653518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor augmented pump (SAP) therapy
Description: Sensor augmented pump (SAP) therapy that includes the use of a study CGM and the participant's personal insulin pump
Study NCT06408428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PANAXIUM MicroECoG
Description: The PANAXIUM microelectrode ( 4x2 cm, 6 micron-thick electrode comprising 128 electrodes (28 500 µm electrodes, 96 30 µm diameter microelectrodes organized as tetrodes and 4 reference electrodes) will be placed on the cortical surface and repositioned every 90 seconds to sample the entire exposed brain surface. During the cortical electrical stimulation mapping phase, the electrode will be left at the edge of the field to detect epileptic discharges induced by stimulation. After resection, a new recording of the residual cortical surface will be made to check for persistent electrical anomalies. In the last 10 patients, the Panaxium microECoG will be compared with a macro-electrode for clinical use.
Study NCT06539286 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Irradiation
Description: three different laser wavelengths will be used
Study NCT05719129 — intervention group
Intervention type: BEHAVIORAL
Intervention: Date With Destiny (DWD) Seminar
Description: 6 days of immersive seminar
Study NCT04068155 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DaRT- Diffusing Alpha-emitters Radiation Therapy
Description: Seed(s) loaded with Radium-224 for local intratumoral irradiation with the destructive power of alpha particles
Study NCT05524714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: solubilized Xanthohumol low dose
Description: single administration of 2 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol and 2 soft gelatine capsules containing only micelles
Study NCT05524714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: solubilized Xanthohumol high dose
Description: single administration of 4 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol
Study NCT05524714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: native Xanthohumol low dose
Description: single administration of 2 hard gelatine capsules each containing 43 mg native Xanthohumol and 2 hard gelatine capsules containing silicon dioxide
Study NCT05524714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: native Xanthohumol high dose
Description: single administration of 4 hard gelatine capsules each containing 43 mg native Xanthohumol
Study NCT06290739 — intervention group
Intervention type: PROCEDURE
Intervention: lymph nodes dissection
Description: Whether lymph nodes dissection should be performed on curative-intent hepatectomy for intrahepatic cholangiocarcinoma is still debated.
Study NCT06398080 — intervention group
Intervention type: DRUG
Intervention: aflibercept 8 mg
Description: No intervention will be provided to study patients. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and following approved clinical guidelines.
Study NCT05756985 — intervention group
Intervention type: PROCEDURE
Intervention: Specimen Collection
Description: Collect and preserve glioblastoma tissue for exploratory analyses to generate hypotheses for future studies.
Study NCT05495425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-12Y gel
Description: NPC-12Y gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
Study NCT05495425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NPC-12Y placebo gel
Description: NPC-12Y placebo gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
Study NCT05980858 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beta-hydroxybutyrate
Description: Each subject receive Beta-hydroxybutyrate 300mg/kg x 3 for five days. After the treatment period effect variables will be examined.
Study NCT05980858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Each subject receive a placebo drink 3 x day for five days. After the treatment period effect variables will be examined.
Study NCT05120752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FODMAP diet
Description: all participants need to follow a low FODMAP diet, the information will be given by a trained dietitian
Study NCT05425277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reciprocal Intervention Teaching (RIT)
Description: RIT is a relatively straightforward, brief NDBI. It employs four simple strategies to target motor imitation and initiating joint attention during play: (1) contingent imitation of the child's verbal and nonverbal behavior, (2) linguistic mapping, (3) direct elicitation of object and gesture imitation following the child's interest, and (4) contingent reinforcement. It has been used at low intensities (e.g., 1-3 hours per week) over short periods of time (e.g., 10-12 weeks) to produce robust changes in pivotal social-communicative skills. RIT is easy to learn and can be implemented with fidelity by undergraduate-level therapists with limited backgrounds in ASD, as well as by caregivers and siblings.
Study NCT05425277 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Routines
Description: The Routines webinar was adapted from a web-based tutorial developed by PI Stone and colleagues (Ibanez et al., 2018). The webinar covers topics such as why everyday routines are important, especially for children with ASD, specific steps for increasing children's participation in routines, and how to use strategies such as visual supports to clarify expectations, and provides numerous video examples of caregivers using different strategies. Providers are also given access to a video library of caregivers using the Daily Routines strategies with their children, as well as a workbook to use with families during treatment.
Study NCT06360523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AI modal
Description: The MRI image will be reviewed by radiologist and AI model(s) respectively. The urologist will combine the results of the two approaches to optimize the biopsy strategy which is expected to result in more accurate diagnosis.
Study NCT06360523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard review
Description: The MRI image will be reviewed by radiologist.
Study NCT06375837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: an alkasite-based restorative material
Description: Cention N
Study NCT06375837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hybrid resin composite
Description: Gradia Direct Anterior
Study NCT06375837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a highly filled flowable resin composite
Description: G-aenial Universal Flo
Study NCT06349525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telescopic overdenture
Description: Maxillary implant supported telescopic overdenture
Study NCT06349525 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Locator overdenture
Description: Maxillary implant supported locator overdenture
Study NCT04923906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aumolertinib
Description: Aumolertinib 110 mg QD in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of every 21-day cycles up to 4\~6 cycles, followed by Aumolertinib 100mg QD with pemetrexed maintenance (500 mg/m2) on Day 1 of every 21-day cycles.~Dose may be reduced to allow for the management of investigational drug related toxicity.
Study NCT04923906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Aumolertinib
Description: Placebo Aumolertinib 110 mg QD Dose may be reduced to allow for the management of investigational drug related toxicity.
Study NCT06007209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Pressure Point
Description: Compression of the subclavian artery against the 1st rib and of the common femoral artery against the pelvis.
Study NCT05353491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology assisted Thinking Healthy Program (THP-TA)
Description: A technology adapted version of the Thinking Healthy Program (THP) delivered by peers using multimedia android based app.